These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23856624)

  • 1. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.
    Mabuka J; Goo L; Omenda MM; Nduati R; Overbaugh J
    AIDS; 2013 Jun; 27(10):1535-44. PubMed ID: 23856624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.
    Martinez DR; Tu JJ; Kumar A; Mangold JF; Mangan RJ; Goswami R; Giorgi EE; Chen J; Mengual M; Douglas AO; Heimsath H; Saunders KO; Nicely NI; Eudailey J; Hernandez G; Morgan-Asiedu PK; Wiehe K; Haynes BF; Moody MA; LaBranche C; Montefiori DC; Gao F; Permar SR
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.
    Milligan C; Omenda MM; Chohan V; Odem-Davis K; Richardson BA; Nduati R; Overbaugh J
    mBio; 2016 Feb; 7(1):e02221-15. PubMed ID: 26838723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR
    J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.
    Ghulam-Smith M; Olson A; White LF; Chasela CS; Ellington SR; Kourtis AP; Jamieson DJ; Tegha G; van der Horst CM; Sagar M
    mBio; 2017 Oct; 8(5):. PubMed ID: 29066544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.
    Kumar A; Giorgi EE; Tu JJ; Martinez DR; Eudailey J; Mengual M; Honnayakanahalli Marichannegowda M; Van Dyke R; Gao F; Permar SR
    PLoS Pathog; 2021 Apr; 17(4):e1009478. PubMed ID: 33798244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.
    Russell ES; Ojeda S; Fouda GG; Meshnick SR; Montefiori D; Permar SR; Swanstrom R
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):511-5. PubMed ID: 23075434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.
    Mullick R; Sutar J; Hingankar N; Deshpande S; Thakar M; Sahay S; Ringe RP; Mukhopadhyay S; Patil A; Bichare S; Murugavel KG; Srikrishnan AK; Goyal R; Sok D; Bhattacharya J
    Retrovirology; 2021 May; 18(1):12. PubMed ID: 33990195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
    Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
    PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversity and Function of Maternal HIV-1-Specific Antibodies at the Time of Vertical Transmission.
    Doepker LE; Simonich CA; Ralph D; Shipley MM; Garrett M; Gobillot T; Vigdorovich V; Sather DN; Nduati R; Matsen FA; Overbaugh JM
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection.
    Goo L; Jalalian-Lechak Z; Richardson BA; Overbaugh J
    J Virol; 2012 Oct; 86(19):10857-61. PubMed ID: 22837204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.
    Kumar A; Smith CEP; Giorgi EE; Eudailey J; Martinez DR; Yusim K; Douglas AO; Stamper L; McGuire E; LaBranche CC; Montefiori DC; Fouda GG; Gao F; Permar SR
    PLoS Pathog; 2018 Apr; 14(4):e1006944. PubMed ID: 29672607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.
    Nakamura KJ; Cerini C; Sobrera ER; Heath L; Sinkala M; Kankasa C; Thea DM; Mullins JI; Kuhn L; Aldrovandi GM
    AIDS; 2013 Jan; 27(3):337-46. PubMed ID: 23296195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.
    Lynch JB; Nduati R; Blish CA; Richardson BA; Mabuka JM; Jalalian-Lechak Z; John-Stewart G; Overbaugh J
    J Virol; 2011 Jun; 85(11):5252-61. PubMed ID: 21411521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.
    Russell ES; Kwiek JJ; Keys J; Barton K; Mwapasa V; Montefiori DC; Meshnick SR; Swanstrom R
    J Virol; 2011 Aug; 85(16):8253-62. PubMed ID: 21593171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of HIV-1 in the face of neutralizing antibodies.
    Blish CA; Blay WM; Haigwood NL; Overbaugh J
    Curr HIV Res; 2007 Nov; 5(6):578-87. PubMed ID: 18045114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.